Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secondary Prevention in Coronary Heart Disease.

Trial Profile

Secondary Prevention in Coronary Heart Disease.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Influenza virus vaccine (Primary) ; ACE inhibitors; Angiotensin type 1 receptor antagonists; Antihyperglycaemics; Atorvastatin; Beta-adrenergic receptor antagonists; Cardiovascular therapies; Diuretics; Ezetimibe; Glimepiride; HMG-CoA reductase inhibitors; Insulin; Metformin; Moxonidine; Nicotine replacement therapy; Simvastatin; Varenicline
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms SPREK!
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2024 as reported by ClinicalTrials.gov record.
    • 08 Aug 2017 Planned Primary completion date changed fr5om 1 Dec 2016 to 1 Dec 2024
    • 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top